Search Results - Ogrinc, F.G

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    PRO2 THE VALUE OF ONASEMNOGENE ABEPARVOVEC GENE-REPLACEMENT THERAPY IN IMPROVING SURVIVAL AND MOTOR FUNCTION AND DECREASING VENTILATORY SUPPORT AND HOSPITALIZATION CONTRASTED TO NATURAL HISTORY FOR SPINAL MUSCULAR ATROPHY TYPE 1

    PRO2 THE VALUE OF ONASEMNOGENE ABEPARVOVEC GENE-REPLACEMENT THERAPY IN IMPROVING SURVIVAL AND MOTOR FUNCTION AND DECREASING VENTILATORY SUPPORT AND HOSPITALIZATION CONTRASTED TO NA... by Dabbous, O, Sproule, D.M, Feltner, D.E, Ogrinc, F.G, Menier, M, Droege, M, Maru, B, Khan, F, Arjunji, R

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    PND9 EVENT-FREE SURVIVAL AND MOTOR MILESTONE ACHIEVEMENT FOLLOWING AVXS-101 AND NUSINERSEN INTERVENTIONS CONTRASTED TO NATURAL HISTORY FOR TYPE I SPINAL MUSCULAR ATROPHY PATIENTS

    PND9 EVENT-FREE SURVIVAL AND MOTOR MILESTONE ACHIEVEMENT FOLLOWING AVXS-101 AND NUSINERSEN INTERVENTIONS CONTRASTED TO NATURAL HISTORY FOR TYPE I SPINAL MUSCULAR ATROPHY PATIENTS by Dabbous, O, Sproule, D.M, Feltner, D.E, Ogrinc, F.G, Menier, M, Droege, M, Maru, B, Khan, F, Arjunji, R

    Published in Value in health
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial

    Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial by Mendell, J.R, Shell, R, Lehman, K.J, McColly, M, Lowes, L.P, Alfano, L.N, Miller, N.F, Iammarino, M.A, Church, K, Spector, S.A, Ogrinc, F.G, Ouyang, H, Kernbauer, E, Shah, S, L’Italien, J, Sproule, D.M, Feltner, D.E, Al-Zaidy, S

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Onasemnogene abeparvovec gene-replacement therapy (GRT) in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update

    Onasemnogene abeparvovec gene-replacement therapy (GRT) in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update by Strauss, K.A, Swoboda, K.J, Farrar, M.A, McMillan, H.J, Parsons, J, Krueger, J.M, Iannaccone, S.T, Chiriboga, C.A, Kwon, J.M, Saito, K, Scoto, M, Baldinetti, F, Schultz, M, Kernbauer, E, Farrow, M, Ogrinc, F.G, Kavanagh, S, Feltner, D.E, McGill, B.E, Spector, S.A, L’Italien, J, Sproule, D.M, Muntoni, F

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Intrathecal administration of AVXS-101 gene-replacement therapy (GRT) for spinal muscular atrophy type 2 (SMA2): Phase 1/2A study (strong)

    Intrathecal administration of AVXS-101 gene-replacement therapy (GRT) for spinal muscular atrophy type 2 (SMA2): Phase 1/2A study (strong) by Finkel, R.S, Day, J.W, Darras, B.T, Kuntz, N.L, Connolly, A.M, Crawford, T.O, Butterfield, R.J, Shieh, P.B, Tennekoon, G, Iannaccone, S.T, Meriggioli, M, Ogrinc, F.G, Kavanagh, S, Kernbauer, E, Whittle, J, L'Italien, J, Kaspar, B, Sproule, D.M, Spector, S.A, Feltner, D.E, Mendell, J.R

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    CM4 TIME TO TREATMENT EFFECT, EVENT-FREE SURVIVAL, AND MOTOR MILESTONE ACHIEVEMENT IN TYPE I SPINAL MUSCULAR ATROPHY PATIENTS TREATED WITH ONASEMNOGENE ABEPARVOVEC (AVXS-101) OR NUSINERSEN CONTRASTED TO NATURAL HISTORY

    CM4 TIME TO TREATMENT EFFECT, EVENT-FREE SURVIVAL, AND MOTOR MILESTONE ACHIEVEMENT IN TYPE I SPINAL MUSCULAR ATROPHY PATIENTS TREATED WITH ONASEMNOGENE ABEPARVOVEC (AVXS-101) OR NU... by Dabbous, O., Sproule, D.M., Feltner, D.E., Ogrinc, F.G., Menier, M., Droege, M., Maru, B., Khan, F., Novack, A., Arjunji, R.

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: